Araştırma Makalesi

MONOCYTE COUNT TO HDL-CHOLESTEROL RATIO MAY BE A NOVEL CARDIOMETABOLIC MARKER IN PATIENTS WITH FUNCTIONAL ADRENAL TUMORS

Cilt: 20 Sayı: 1 27 Ağustos 2019
PDF İndir
EN TR

MONOCYTE COUNT TO HDL-CHOLESTEROL RATIO MAY BE A NOVEL CARDIOMETABOLIC MARKER IN PATIENTS WITH FUNCTIONAL ADRENAL TUMORS

Öz

OBJECTIVE: The monocyte count to HDL-Cholesterol ratio (MHR) was increased in patients with cardiovascular disease and, showed as an indicator of cardiovascular risk factors. Functional adrenal tumor and even nonfunctional adrenal adenomas are associated with an increased risk for cardiovascular disease. This is the first study to evaluate the MHR value in patients with adrenal tumors, and examine its relation with cardiometabolic risk factors.

MATERIAL AND METHODS: Twenty-four patients with functional adrenal tumor (10 Cushing syndrome, 12 pheochromocytoma, and 2 primary hyperaldosteronism), patients with non-functional adrenal adenoma (n=33) and, control subjects (n=50) were included. Anthropometric, hormonal and biochemical results, lipid panel, fasting plasma glucose (FPG), blood pressure (BP), blood cell counts, high-sensitivity C-reactive protein (hs-CRP), and carotid intima-media thickness (CIMT) were compared.

RESULTS: Mean age (51.14±2.03 vs 54.01±9.37 years), sex distribution (female 66.7 % vs 73.8 %), and body mass index (31.12±3.38 vs 30.46±2.96 kg/m2) were similar between adrenal tumor and control group (respectively, p>0.05). The MHR value was higher in the functional tumor group compared with the non-functional adenoma and control group (13.79±3.14, 10.19±2.84 vs 10.08±1.82, respectively, p<0.05). MHR value was similar between the non-functional adenoma and controls (p>0.05). MHR value was positively correlated with systolic BP (r=0.480, p<0.001), diastolic BP (r=0.452, p<0.001), FPG (r=0.333, p=0.001), hs-CRP (r=0.538, p=0.001) and, urinary normetanephrine concentrations (r=0.302, p=0.043). Functional adrenal tumor with cardiovascular disease had higher MHR value compared with those without cardiovascular disease (14.69±2.67 vs 11.84±2.57, p<0.05).

CONCLUSIONS: The MHR value was increased in patients with functional adrenal tumor; however it did not increase in patients with nonfunctional adenoma. MHR value was correlated with cardio-metabolic risk factors such as FPG, BP, and hs-CRP. The MHR value suggests as a predictive marker for cardiometabolic risk factors in functional adrenal tumors.

Anahtar Kelimeler

Kaynakça

  1. Prof Dr Deniz Gökalp, Acıbadem Üniversitesi, Endokrinoloji ve MetabolizmaProf Dr Kevser Onbaşı, Kütahya Evliya Çelebi Üniversitesi, Endokrinoloji ve MetabolizmaDoç Dr Göknur Yorulmaz, Eskişehir Osmangazi Üniversitesi, Endokrinoloji ve Metabolizma

Ayrıntılar

Birincil Dil

İngilizce

Konular

Klinik Tıp Bilimleri

Bölüm

Araştırma Makalesi

Yayımlanma Tarihi

27 Ağustos 2019

Gönderilme Tarihi

13 Mayıs 2019

Kabul Tarihi

22 Temmuz 2019

Yayımlandığı Sayı

Yıl 2019 Cilt: 20 Sayı: 1

Kaynak Göster

APA
Beysel, S., Çalışkan, M., Kızılgül, M., Özçelik, Ö., Çilekar, M., Özbek, M., & Çakal, E. (2019). MONOCYTE COUNT TO HDL-CHOLESTEROL RATIO MAY BE A NOVEL CARDIOMETABOLIC MARKER IN PATIENTS WITH FUNCTIONAL ADRENAL TUMORS. Kocatepe Tıp Dergisi, 20(1), 201-207. https://doi.org/10.18229/kocatepetip.563553
AMA
1.Beysel S, Çalışkan M, Kızılgül M, vd. MONOCYTE COUNT TO HDL-CHOLESTEROL RATIO MAY BE A NOVEL CARDIOMETABOLIC MARKER IN PATIENTS WITH FUNCTIONAL ADRENAL TUMORS. KTD. 2019;20(1):201-207. doi:10.18229/kocatepetip.563553
Chicago
Beysel, Selvihan, Mustafa Çalışkan, Muhammed Kızılgül, vd. 2019. “MONOCYTE COUNT TO HDL-CHOLESTEROL RATIO MAY BE A NOVEL CARDIOMETABOLIC MARKER IN PATIENTS WITH FUNCTIONAL ADRENAL TUMORS”. Kocatepe Tıp Dergisi 20 (1): 201-7. https://doi.org/10.18229/kocatepetip.563553.
EndNote
Beysel S, Çalışkan M, Kızılgül M, Özçelik Ö, Çilekar M, Özbek M, Çakal E (01 Ağustos 2019) MONOCYTE COUNT TO HDL-CHOLESTEROL RATIO MAY BE A NOVEL CARDIOMETABOLIC MARKER IN PATIENTS WITH FUNCTIONAL ADRENAL TUMORS. Kocatepe Tıp Dergisi 20 1 201–207.
IEEE
[1]S. Beysel vd., “MONOCYTE COUNT TO HDL-CHOLESTEROL RATIO MAY BE A NOVEL CARDIOMETABOLIC MARKER IN PATIENTS WITH FUNCTIONAL ADRENAL TUMORS”, KTD, c. 20, sy 1, ss. 201–207, Ağu. 2019, doi: 10.18229/kocatepetip.563553.
ISNAD
Beysel, Selvihan - Çalışkan, Mustafa - Kızılgül, Muhammed - Özçelik, Özgür - Çilekar, Murat - Özbek, Mustafa - Çakal, Erman. “MONOCYTE COUNT TO HDL-CHOLESTEROL RATIO MAY BE A NOVEL CARDIOMETABOLIC MARKER IN PATIENTS WITH FUNCTIONAL ADRENAL TUMORS”. Kocatepe Tıp Dergisi 20/1 (01 Ağustos 2019): 201-207. https://doi.org/10.18229/kocatepetip.563553.
JAMA
1.Beysel S, Çalışkan M, Kızılgül M, Özçelik Ö, Çilekar M, Özbek M, Çakal E. MONOCYTE COUNT TO HDL-CHOLESTEROL RATIO MAY BE A NOVEL CARDIOMETABOLIC MARKER IN PATIENTS WITH FUNCTIONAL ADRENAL TUMORS. KTD. 2019;20:201–207.
MLA
Beysel, Selvihan, vd. “MONOCYTE COUNT TO HDL-CHOLESTEROL RATIO MAY BE A NOVEL CARDIOMETABOLIC MARKER IN PATIENTS WITH FUNCTIONAL ADRENAL TUMORS”. Kocatepe Tıp Dergisi, c. 20, sy 1, Ağustos 2019, ss. 201-7, doi:10.18229/kocatepetip.563553.
Vancouver
1.Selvihan Beysel, Mustafa Çalışkan, Muhammed Kızılgül, Özgür Özçelik, Murat Çilekar, Mustafa Özbek, Erman Çakal. MONOCYTE COUNT TO HDL-CHOLESTEROL RATIO MAY BE A NOVEL CARDIOMETABOLIC MARKER IN PATIENTS WITH FUNCTIONAL ADRENAL TUMORS. KTD. 01 Ağustos 2019;20(1):201-7. doi:10.18229/kocatepetip.563553

88x31.png
Bu Dergi Creative Commons Atıf-GayriTicari-AynıLisanslaPaylaş 4.0 Uluslararası Lisansı ile lisanslanmıştır.